港股異動丨蘋果概念股普跌,舜宇跌超3%,蘋果大中華區季度營收不及預期
港股市場蘋果概念股集體下跌,其中,丘鈦科技跌近5%,舜宇跌超3%,高偉電子跌2%,比亞迪電子和瑞聲科技跌超1%。蘋果公佈,截至9月28日止第四財季,營收949.3億美元,分析師預期943.6億美元,同比增長6%。第四財季大中華區營收150.3億美元,低於分析師預期的158億美元。蘋果第四財季純利僅錄得147.3億美元,同比倒退35.8%,主要由於期內須支付一筆總額達102億美元的税務開支,涉及2016年公司在愛爾蘭的税務處理問題;期內經調整後每股盈利報1.64元,同比增長12%;整體營運開支報142.9億美元,少過分析員預期的143.5億美元。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.